Tempus AI Gets FDA Green Light for Simpler Tumor-Only Cancer Test
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.
IFF is selling its food ingredients unit to CVC for $4.3B to focus on core business and reduce debt, while staying partially invested.
Blue Origin’s New Glenn rocket burst into flames during a test, delaying Amazon’s satellite plans and AST SpaceMobile’s launch schedule. Space stocks drop sharply.
Agios scraps LR-MDS drug tebapivat after weak results but continues sickle cell trials; safety was good.
NetApp beat earnings, grew revenue, boosted cloud & AI products, and raised strong 2027 outlook above expectations.
Aerie is booming, but American Eagle struggles. Revenue hit a record, yet weak sales and cautious shoppers pushed shares down.